Spectral Analysis of Bortezomib

doi:10.11938/cjmr20170106

Abstract

Abstract: Ultraviolet (UV) spectrum, infrared (IR) spectrum, electrospray ionization-mass spectra (ESI-MS) and nuclear magnetic resonance (NMR) spectra (i.e., ¹H NMR, ¹³C NMR, DEPT, ¹H-¹H COSY, ¹H-¹³C HSQC and ¹H-¹³C HMBC) of bortezomib were collected and interpreted. All ¹H and ¹³C NMR signals were assigned. The structure of the compound was preliminarily determined.

Key words: bortezomib, nuclear magnetic resonance (NMR), assignment, ultraviolet spectrum, structural elucidation, infrared spectrum

CLC Number:

O482.53

FENG Xiao-hu, YU Shui-tao, XIA Zheng-jun, CHEN Zai-xin. Spectral Analysis of Bortezomib[J]. Chinese Journal of Magnetic Resonance, 2017, 34(1): 43-51.

References

[1] LAWRENCE J M, JACK H L, WENGEN W, et al. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors[J]. J Med Chem, 2011, 54(13):4365-4377.
[2] JANCA, MICHAL, DOBROVOLNY, et al. Methods for preparing bortezomib and intermediates used in its manufacture:WO, 004350[P]. 2009-01-09.
[3] LI Z, MAO H, ZHONG J F. Graphical synthetic routes of bortezomib[J]. Chinese Journal of Pharmaceuticals, 2012, 43(5):393-395. 李忠, 毛化, 钟静芬. 硼替佐米合成路线图解[J]. 中国医药工业杂志, 2012, 43(5):393-395.
[4] MELISSA A B, CHIHUI A, JONATHAN A E. Asymmetric copper-catalyzed synthesis of γ-amino boronate esters from N-tert-butanesulfinyl aldimines[J]. J Am Chem Soc, 2008, 130(22):6910-6911.
[5] FU L H, WANG L, YU Y C, et al. Induction of acute myelogenous leukemia cell apoptosis by bortezomib and its effect on SALL4 geneExpression[J]. Chin Pharm J, 2012, 47(4):274-278. 傅雷华, 王兰, 喻依川, 等. 硼替佐米诱导急性髓性白血病细胞凋亡及对SALL4基因表达的影响[J]. 中国药学杂志, 2012, 47(4):274-278.
[6] PICKERSGILL I F, BISHOP J, KOELLNER C, et al. Synthesis of boronic ester and acid compounds:WO, 097809[P]. 2005-10-20.
[7] PALLE, RAGHAVENDRACHARYULU V, KADABOINA, et al. Bortezomib and process for producing same:WO, 036281[P]. 2009-03-19.
[8] 赛福伦公司. 蛋白酶体抑制剂及其制备、纯化和应用的方法:中国, 102725300 A[P], 2012-10-10.
[9] BRUCE D D, MOHAMED I, SANKAR C, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer[J]. J Med Chem, 2008, 51(4):1068-1072.
[10] MARINE P, MARIE-AGNÈS L, JEAN S, et al. Further characterization of a putative serine protease contributing to the c-secretase cleavage of b-amyloid precursor protein[J]. Bioorg Med Chem, 2013, 21(4):1018-1029.
[11] RAO, DHARMARAJ, RAMACHANDRA, et al. Process for preparing of bortezomib:WO, 041324[P]. 2014-03-20.
[12] CONG Y W, LUAN C F, CHEN H, et al. Synthesis of bortezomib[J]. Chinese Journal of New Drugs, 2014, 23(6):698-700. 丛艳伟, 栾春芳, 陈宏, 等. 硼替佐米的合成[J]. 中国新药杂志, 2014, 23(6):698-700.
[13] 千禧药品公司. 硼的酯和酸化合物的合成:中国, 200580017645.5[P], 2007-05-09.
[14] 孙江涛. 一种硼替佐米的合成方法:中国, 101812026 B[P], 2013-08-28.
[15] ANDREY S I, ANNA A Z SERGEY V S. A convergent approach to synthesis of bortezomib:the use of TBTU suppresses racemization in the fragment condensation[J]. Tetrahedron, 2009, 65(34):7105-7108.
[16] SATISH K, VENUGOPAL V D, PARENDU D R, et al. Process for the Preparation of Bortezomib:US, 0085277[P]. 2013-04-04.
[17] ZHENG D Q, ZHANG L J, ZHANG Z Y. Synthesis of bortezomib[J]. Chinese Journal of Pharmaceuticals, 2015, 46(3):227-229. 郑德强, 张利剑, 张治云. 硼替佐米的合成[J]. 中国医药工业杂志, 2015, 46(3):227-229.
[18] JI A C, HAN H, WANG C Q, et al. Synthesis of bortezomib[J]. Pharmaceutical and Clinical Research, 2014, 22(2):121-123. 纪安成, 韩航, 王超群, 等. 硼替佐米的合成工艺改进[J]. 药学与临床研究, 2014, 22(2):121-123.
[19] 宁永成. 有机化合物结构鉴定与有机波谱学[M]. 北京:科学出版社, 2000.
[20] 赵天增. 核磁共振图谱[M]. 北京:北京大学出版社, 1982.